-
Deferasirox Fe3+ chelate Workflow Guide
2026-08-29
Build reproducible iron overload and myeloid differentiation assays with a defined ferric deferasirox complex, while separating chelate exposure from apo-chelator biology. This guide combines practical solvent handling, oxygen-sensitive ROS measurements, and controls informed by recent NF-κB research.
-
ML385: NRF2 Inhibition in Cancer and Redox Research
2026-08-29
ML385 is a selective NRF2 inhibitor for dissecting antioxidant signaling, non-small cell lung cancer resistance, and redox-dependent phenotypes. This workflow combines dose–response testing with target-engagement and functional assays, while extending the compound’s use to NRF2-dependent inflammatory osteolysis research.
-
Staurosporine Workflows for Kinase and Cancer Research
2026-08-28
Build more informative kinase, apoptosis, migration, and angiogenesis assays with Staurosporine, a broad-spectrum perturbation tool rather than a pathway-specific inhibitor. This workflow shows how to separate cytotoxicity from signaling effects while applying recent TNBC metastasis findings to practical experimental design.
-
GSDMC Drives Stemness and Immune Evasion in PDAC
2026-08-28
The reference study identifies Gasdermin C (GSDMC) as a nuclear transcriptional regulator of pancreatic ductal adenocarcinoma rather than only a pyroptosis-associated pore-forming protein. Its findings connect ADAM17-dependent cleavage, cancer stemness, metastasis, and CXCL9-linked immune evasion, suggesting a route to improve responses to KRASG12D inhibition and PD-1 blockade.
-
GSDMC Drives Stemness and Immune Evasion in PDAC
2026-08-27
A 2024 Advanced Science study identifies Gasdermin C as a nuclear regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion rather than merely a pyroptosis-associated pore-forming protein. The work connects ADAM17-dependent GSDMC cleavage to CXCL9-mediated immune remodeling and improved responses to KRASG12D inhibition and PD-1 blockade in preclinical models.
-
Dual-Action Inhibitors Reprogram p38α Dephosphorylation
2026-08-27
The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also accelerate WIP1-mediated removal of the activation-loop phosphate. Biochemical assays and X-ray structures connect this effect to an inhibitor-stabilized activation-loop conformation, offering a mechanistic framework for interpreting p38 inhibitor potency and selectivity.
-
Nutlin-3a and the p53–Ferroptosis Frontier
2026-08-26
Nutlin-3a is more than a conventional MDM2 inhibitor: it is a controllable chemical probe for testing how p53 pathway activation intersects with cell-cycle control, apoptosis, and ferroptosis. This thought-leadership perspective connects MDM2–p53 biology with the miR-18a–ALOXE3 axis in glioblastoma and offers a practical framework for translational validation, biomarker selection, and model design.
-
PD0325901: A MEK-to-Embryo Assay Framework
2026-08-26
PD0325901 is a selective MEK inhibitor for dissecting ERK signaling, proliferation, and apoptosis. This article develops a cautious assay framework linking pharmacologic pathway perturbation with WDR36-dependent glycolytic control of trophectoderm development.
-
BIBR 1532: A Telomerase Assay Strategy
2026-08-25
BIBR 1532 is a selective telomerase inhibitor that connects hTERT inhibition with telomere-state and leukemia-cell fate measurements. This article presents a staged assay strategy and explains how recent CF10–EdU findings can improve interpretation without conflating telomere attrition with direct telomerase inhibition.
-
CA-074 Workflow for Cathepsin B Mechanisms
2026-08-25
CA-074 combines nanomolar cathepsin B potency with strong selectivity, making it useful for separating CTSB-dependent effects from broader lysosomal protease activity. This guide translates the compound into practical necroptosis, cancer metastasis, neurotoxicity, and immune response workflows, with assay controls and troubleshooting strategies.
-
I-BET151: BET Inhibition Workflow Guide
2026-08-24
Build reproducible I-BET151 experiments around BET-dependent transcription, apoptosis, and cell-cycle phenotypes. This guide also shows how to translate super-enhancer and SLC7A11 findings into a hypothesis-driven prostate cancer workflow without overstating what the reference study directly proved.
-
EZ Cap™ Firefly Luciferase mRNA: Delivery Calibrator
2026-08-23
EZ Cap™ Firefly Luciferase mRNA can serve as more than a reporter: it is a standardized payload for separating delivery, endosomal escape, translation, and assay variability. This article connects Cap 1 mRNA design with rational lipid nanoparticle screening and in vivo bioluminescence imaging.
-
iRhom2, Odorant Receptors, and Olfactory Adaptation
2026-08-22
Azzopardi and colleagues identify iRhom2 as a distinctive regulator of olfactory sensory neurons, linking odorant receptor signaling with ADAM17-dependent activity adaptation. Their combination of knockout mice, transcriptomics, spatial validation, and a receptor activation model suggests a feedback mechanism in which odor exposure reduces iRhom2 expression while reshaping receptor- and activity-related transcription.
-
Sulfachloropyridazine: Applied Research Workflows
2026-08-21
Sulfachloropyridazine supports mechanistic DHPS studies, antimicrobial susceptibility testing, combination-antibiotic experiments, and microbiome-focused infection research. This workflow-oriented guide connects controlled bench assays with the integrated microbiota and metabolomics strategy used in Eimeria-infected chickens.
-
Caffeine Workflows for Cancer and Metabolic Research
2026-08-21
Caffeine supports controlled studies of cancer cell line inhibition, energy metabolism modulation, and hypothalamic signaling, with practical solubility advantages for aqueous workflows. This guide pairs dose-response design and troubleshooting with a clearly bounded translation of ALDH2 activator research into better assay strategy.